Abstract
Purpose: ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain poorly understood. Experimental Design: The clinical relevance of ARID1A loss and CD8+ T-cell infiltration was evaluated in three cohorts [Zhongshan Hospital, Fudan University (ZSHS), n = 135; Fudan University Shanghai Cancer Center (FUSCC), n = 118; and IMvigor210, n = 274]. Immune microenvironment profiling was performed via IHC in the ZSHS cohort and transcriptomics in the IMvigor210 cohort. The Shanghai-sequencing cohort (n = 134) provided genomic characterization of ARID1A-loss patients. Results: ARID1A loss did not affect overall survival and CD8+ T-cell infiltration in both ZSHS and FUSCC cohorts. Only in ARID1A-loss urothelial carcinoma, high infiltration of CD8+ T cells yielded favorable outcomes (ZSHS cohort, log-rank P = 0.010; FUSCC cohort, log-rank P = 0.015). Moreover, ARID1Aloss CD8high patients displayed improved survival following adjuvant chemotherapy (log-rank P = 0.015) and PD-1/PD-L1 blockade (log-rank P = 0.020). In ARID1A-loss urothelial carcinoma, the enhanced antitumor function of CD8+ T cells might be affected by tertiary lymphoid structures. Furthermore, ARID1Aloss CD8high patients exhibited an antitumor immune contexture characterized by decreased immune-suppressive cells such as DC-SIGN+ tumor-associated macrophages, PDPN+ cells, and TGF-β+ cells, as well as lower expression of checkpoints such as B7-H3 and B7-H4. Conclusions: The combination of ARID1A loss plus CD8+ T-cell infiltration indicated a favorable prognosis and responsiveness to both chemotherapy and immunotherapy. These findings provide valuable insights for developing novel therapeutic strategies and improving treatment stratification for urothelial carcinoma.
Funding Information
  • National Natural Science Foundation of China (82272786, 82272930, 82372793, 82373276)
  • China Postdoctoral Science Foundation (BX20230091, 2024M760547)
  • Natural Science Foundation of Shanghai Municipality (22ZR1413400, 23ZR1440300, 23ZR1411700, 24SF1901304)
  • Shanghai Sailing Program (24YF2705400, 24YF2706000)
  • Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission (24CGA07)
  • Shanghai Municipal Health Bureau (202340127, 202340195, 20224Y0232)
  • Beijing Xisike Clinical Oncology Research Foundation (Y-Gilead2024-PT-0098)
  • Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation (YJYQ201802)
  • Shanghai Anticancer Association EYAS Project (SACA-CY22B02, ZYJH202309, SACA-CY24C10)
  • Youth Foundation of Zhongshan Hospital affiliated with Fudan University (ZSZP202405)
  • Chongqing Postdoctoral Program for Innovative Talents (CQBX202426)
  • Key Project of Young Doctor Incubation Program of the Second Affiliated Hospital of Army Medical University (2024YQB024)

This publication has 50 references indexed in Scilit: